About us IEP, founded in 1999 as a privately held company with a focus on biocatalysis, is a world-leader in bioreduction technology and has commercialized more than 10 large scale bioreduction processes in the past five years. With more than 100 enzymes available, the synthesis of very broad range of chiral alcohols and derivatives can be created. IEP offers customized solutions for process development and support in enzymatic screening, isolation, purification and characterization. In March 2010, IEP became Cambrex IEP. Cambrex IEP offers a broad biocatalysis platform to the pharmaceutical industry. Cambrex IEP remains committed to innovation, reliability and first-class science in a strong competitive environment of “white biotechnology”. About Cambrex Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including drug product intermediates, active pharmaceutical ingredients (APIs), advanced intermediates, enhanced drug delivery and other products for branded and generic pharmaceuticals. Cambrex currently employs approximately 850 people worldwide. For more information, please visit www.cambrex.com.
Cambrex Karlskoga AB
Björkborns Industriområde SE-691 85 Karlskoga Sweden
Tel: +46 586 78 30 00 Fax: +46 586 78 30 09
|
